ArticleNeuroscience2025
Integrated multi-omics analysis reveals immunovascular mechanisms of the placenta-maternal brain axis and lifespan neurobehavior changes in a mouse model of preeclampsia.
Article in Neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Preeclampsia (PE) is a hypertensive disorder of pregnancy, among the leading global drivers of maternal morbidity. PE can precipitate neuropsychiatric risk, including for peripartum anxiety, depression, and cognitive problems. To investigate mechanisms underlying psycho-obstetric risk in PE, we examined maternal metabolic, placental, brain, and behavioral changes in our chronic vasopressin (AVP) infusion PE mouse model (C57Bl6/J). Elevated maternal AVP secretion predicts PE in humans, and chronic AVP administration is sufficient to phenocopy immune, obstetric, and renal phenotypes of PE in pregnant mice. Late-pregnancy metabolomics (N = 4-6/condition/tissue) revealed no significant disruptions in plasma, but 33 changed metabolites were changed in AVP mouse placenta, implicating altered protein, energy, and nutrient functions. Placental RNA sequencing (RNA-seq; N = 3/condition) revealed 140 differentially expressed genes (DEGs), with pathway analyses highlighting changes in structural and metabolic remodeling. Placental multi-omic integration (RNA-seq and metabolomics) identified altered purine metabolism. Analysis of RNA-seq-predicted placental secretome suggested altered immunovascular factors (e.g., C2CD4, KLK1B1). In late-gestation maternal brain, RNA-seq (N = 3/condition) revealed extensive gene suppression in the hypothalamic paraventricular nucleus (PVN, 329 DEGs; 322 down-regulated) and frontal cortex (114 DEGs; 113 down-regulated), implicating altered signaling and immune-vascular pathways, respectively. AVP increased antepartum exploratory behavior without changing depressive-like or hedonic behaviors. Spatial memory deficits in aged postpartum AVP dams were also significant and associated with molecular changes in the hippocampus. Overall, the AVP model of PE induces placental and maternal brain changes, invoking immune and vascular mechanisms. This work identifies potential mechanisms underlying PE impacts on maternal brain, with implications for associated mental health challenges.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.